ELEVATING TOMORROW’S STANDARD OF CANCER CARE TODAY

 

WELCOME TO ABALYTICS ONCOLOGY

10 million people die from cancer every year. It remains the cause of every sixth death. At Abalytics Oncology, our vision is to redefine the standard of cancer care in the 21st century.

 

Core Values

How do you approach cancer treatment in the age of artificial intelligence? Where do you choose to focus?
At Abalytics Oncology, three simple values drive every action we take.

Overall survival

Quality of life

Greater Understanding

Strategic Missions for 2025 and Beyond

01

Bring best-in-class anti-CTLA4 to patients in 2025

02

Develop  targeted next-generation antibody-based therapies

03

Build Data Model, Pipeline, And System Integrations to Solve Cancer Immune Resistance

Abalytics Stands for Antibody Data Analytics

Abalytics Intelligence

Sequences

Clinical Trials

Structures

Publications

Patents

Biomarkers

Companies

Technologies

Investments

Code

Real-world information, in real-time

Artificial Intelligence generates infinite options, which human intelligence evolved to constrain.

Abalytics Algorithms

Target selection

Antibody design

Lead identification

Translational modeling

Treatment optimization

Resource allocation

Abalytics Therapies

Immune Checkpoint Inhibitors

Antibody Drug Conjugates

Targeted Therapies

We use computational antibody design and biomolecular engineering to develop better treatments

Pipeline

ABAO2 primes the immune system for the new age of targeted combination therapies

Program

Discovery

IND-Enabling Studies

Status

Best-in-Class Immune Checkpoint Inhibitor with Improved Safety and Efficacy

ABAO2

Anti-CTLA4

Ready for Phase 1

Next generation antibody-based pMHC targeted therapies

ABAO3

mKRAS

R&D

ABAO4

PRAME

R&D

ABAO5

MAGE-A4

R&D

ABAO6

NY-ESO-1

R&D

Abalytics Oncology Therapies target the black box that is cancer immune resistance

Abalytics Oncology Therapies

Immune Checkpoint Inhibitors

Antibody Drug Conjugates

Targeted Therapies

Cancer Immune Resistance

Suppression

Blockage and downregulation of immune response

Exhaustion

Body loses key line of
defense

Evasion

Tumor cells are invisible to the
immune system

SUCCESS OUTCOMES

Tumor shrinkage

Durable responses

Overall survival

Our Founders

Akshay Paintal

CEO

Shay combines a track record of computational antibody design and development with a decade of experience implementing data analytics systems across diverse healthcare settings. He is credited with the invention of Omoprubart and has executed on over 15 other cutting edge drug development programs, including TY027. Before formalizing a system for computational antibody design in the Sasisekharan Lab at MIT’s Koch Institute for Integrative Cancer Research, Shay developed technology solutions for public and private sector clients exploring practical applications of artificial intelligence. An ex-Deloitte Systems Integration consultant, Shay holds a Bachelor of Science in Chemical and Biomolecular Engineering from Johns Hopkins University.

Manish Potti

Chief Business Officer

Manish has a track record of execution in the biopharmaceutical industry. He was the Chief Business Officer of Shinmei Therapeutics, a CNS focused company. He was previously the President and co- founder of Ionogenic Pharmaceuticals. At Inorganic, Manish took a brownfield project through FDA facility approval, directed the R&D strategy, in-licensed assets, and grew the revenue to a stable base. He was also the head of business development of Epic Pharma, where he led the sale process of the company to Humanwell Healthcare of China in 2016. Since 2016, he has been actively investing and managing portfolio companies in biotech, spec pharma, and medtech. Manish has overseen R&D,…..

Contact us

Connect with us about reshaping the future of cancer care today.

Scroll to Top

Shay combines a track record of successful computational antibody design with a decade of experience founding data-driven companies. He is the inventor of Omoprubart and has executed on over 15 computational antibody design and development programs including TY027. Shay developed computational antibody design systems at the Sasisekharan Lab in MIT’s Koch Institute for Integrative Cancer Research and has built diverse technology solutions for government and big pharma clients exploring artificial intelligence applications. An ex-Deloitte technology consultant, Shay holds a Bachelor of Science in Chemical and Biomolecular Engineering from Johns Hopkins University.

Manish has a track record of execution in the biopharmaceutical
industry. He was the Chief Business Officer of Shinkei Therapeutics, a CNS focused company. He was previously the President and co-founder of Innogenix Pharmaceuticals. At Innogenix, Manish took a brownfield project through FDA facility approval, directed the R&D strategy, in-licensed assets, and grew the revenue to a stable base. He was also the head of business development of Epic Pharma, where he led the sale process of the company to Humanwell Healthcare of China in 2016. Since 2016, he has been actively investing and managing portfolio companies in biotech, spec pharma, and medtech. Manish has overseen R&D, regulatory, commercial, and manufacturing in his career. He has extensive experience in M&A, BD, venture capital, and financing. He began his career in banking and as a trader at a hedge fund. Manish holds a Bachelor of Science in Molecular Biology from Johns Hopkins University, and a Master’s in Financial Engineering from New York University.